更为重要的是，通过CD40L这种东西增强的TIL细胞更像是“干细胞”，可以有更加持久的抗癌能力。目前美国莫菲特癌症中心正在开展一项临床试验，以检测这个方法在非小细胞肺癌患者的应用，也就是说CD40L增强型TIL有望能成为下一代TIL疗法的标准。

上面的这个图表来自本文的参考文献，看起来花花绿绿比较难以看懂。这里咱们只是用来佐证研究者的结论：他们使用一种名为CD40L的东西，可以将肿瘤病灶里提取的TIL培养效率提升，没有使用CD40L则TIL只在33%的样本里成功生长，而使用CD40L则TIL ...

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on ...

Eledon Pharmaceuticals, Inc.’s ELDN share price has surged by 7.68%, which has investors questioning if this is right time to ...

Frexalimab was well tolerated and maintained disease control over two years in adults with relapsing MS in an open-label ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of ...

TNX-1500 is an investigational, humanized Fc-modified IgG4 anti-CD40L antibody with high affinity for the CD40 ligand. CD40L is an attractive drug development target for transplant ...

TNX-1500 is an investigational, humanized Fc-modified IgG4 anti-CD40L antibody with high affinity for the CD40 ligand. Shares of Tonix Pharmaceuticals are up 3% in pre-market trade on Wednesday.

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...